Inhibikase Therapeutics (IKT) Return on Capital Employed [ROCE] (2021 - 2026)
Inhibikase Therapeutics' Return on Capital Employed [ROCE] came in at -41.36% for Q2 2026, up 12.02 percentage points from -53.39% a year earlier but down 9.18 percentage points from the prior quarter.
Powered by 
Analysis
Inhibikase Therapeutics (IKT) Return on Capital Employed [ROCE] (2021 - 2026) Analysis & Trends
For FY2025, Inhibikase Therapeutics' Return on Capital Employed [ROCE] was -39.49%, up 14.63 percentage points from FY2024.
- Return on Capital Employed [ROCE] carries a four-year change of +20.60 percentage points (FY2021 to FY2025).
- Going back by year, Return on Capital Employed [ROCE] was -54.13% in FY2024 (+69.25 pp), -123.38% in FY2023 (-62.97 pp), -60.41% in FY2022 (-0.32 pp) and -60.09% in FY2021.
- The five-year range for quarterly Return on Capital Employed [ROCE] is -1184.15% (Q3 2024) to -24.37% (Q3 2021).
- Year-over-year, Return on Capital Employed [ROCE] has increased for seven consecutive quarters, with an average year-over-year change of +78.84 percentage points over the last eight quarters.
- The fastest year-over-year change in Return on Capital Employed [ROCE] over five years came in Q3 2025 (a gain of 1118.21 percentage points), and the weakest in Q3 2024 (a drop of 1068.90 percentage points).
- Business Quant data shows IKT's Return on Capital Employed [ROCE] at -32.19% (Q1 2026), -42.57% (Q4 2025) and -65.95% (Q3 2025) in the three quarters before Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn | 46.74% |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn | 17.83% |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn | 17.92% |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn | 6.28% |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn | 19.32% |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn | 9.54% |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn | 16.66% |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn | -5.97% |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn | 11.86% |
| 10 | Inhibikase Therapeutics | 349.14 Mn | -236.33 Mn | - | -41.36% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -41.36% |
| Mar 31, 2026 | -32.19% |
| Dec 31, 2025 | -42.57% |
| Sep 30, 2025 | -65.95% |
| Jun 30, 2025 | -53.39% |
| Mar 31, 2025 | -43.70% |
| Dec 31, 2024 | -59.87% |
| Sep 30, 2024 | -1,184.15% |
| Jun 30, 2024 | -304.43% |
| Mar 31, 2024 | -235.64% |
| Dec 31, 2023 | -157.50% |
| Sep 30, 2023 | -115.25% |
| Jun 30, 2023 | -87.76% |
| Mar 31, 2023 | -76.21% |
| Dec 31, 2022 | -78.60% |
| Sep 30, 2022 | -67.09% |
| Dec 31, 2021 | -36.81% |
| Sep 30, 2021 | -24.37% |
| Jun 30, 2021 | -24.86% |
| Mar 31, 2021 | -50.35% |
API Access
Inhibikase Therapeutics Return on Capital Employed [ROCE] API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=return-on-capital-employed-%5Broce%5D&ticker=IKT&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "return-on-capital-employed-[roce]", "ticker": "IKT", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=return-on-capital-employed-%5Broce%5D&ticker=IKT&period=max&api_key=YOUR_API_KEY");
const data = await res.json();